Olaparib(奥拉帕尼)有哪些禁忌
病情描述:Olaparib(奥拉帕尼)有哪些禁忌
展开2024-05-09 09:31:58
1回答
1378浏览
好问题
病情描述:Olaparib(奥拉帕尼)有哪些禁忌
展开2024-05-09 09:31:58
1回答
1378浏览
好问题
问药网
问药网官方药师
Olaparib(奥拉帕尼)有哪些禁忌,Olaparib(Olaparib)禁忌为:1、对奥拉帕利或药物中的任何成分过敏的患者禁用;2、孕妇患者禁用;3、哺乳期妇女患者禁用。
Olaparib, also known as Olaparib, is a medication that has shown promising results in the treatment of certain types of cancers, including ovarian, breast, pancreatic, primary peritoneal, and prostate cancers. However, like any drug, Olaparib has certain contraindications or situations in which its use is not recommended. In this article, we will explore the contraindications of Olaparib, which are important to be aware of to ensure the safe and effective use of this medication.
1. Contraindications of Olaparib
Olaparib is contraindicated in individuals who have experienced hypersensitivity or an allergic reaction to the drug or any of its components. People with a known hypersensitivity to Olaparib should avoid taking this medication to prevent adverse reactions.
2. Use in Pregnancy and Breastfeeding
The use of Olaparib during pregnancy is not recommended. Studies have not been conducted to evaluate the potential risks and effects of Olaparib on pregnant women or unborn babies. Therefore, if you are pregnant or planning to become pregnant, it is crucial to discuss the risks and benefits of Olaparib with your healthcare provider before considering its use.
Similarly, the use of Olaparib during breastfeeding is not recommended. It is unknown whether Olaparib is excreted in human breast milk or the potential risks it may pose to infants. Considering this, breastfeeding mothers should consult their healthcare providers to explore alternative treatment options or suspend breastfeeding while using Olaparib.
3. Severe Hepatic Impairment
As Olaparib is primarily metabolized in the liver, individuals with severe hepatic impairment should exercise caution when taking this medication. Severe hepatic impairment refers to a significant decrease in liver function, usually indicated by abnormal liver function tests. In such cases, the use of Olaparib may lead to increased exposure to the drug, potentially resulting in adverse effects. It is essential for individuals with severe hepatic impairment to discuss the risks and benefits of Olaparib with their healthcare providers before initiating treatment.
4. Renal Impairment
Although Olaparib is mainly eliminated from the body through the liver, it is also partially excreted via the kidneys. Therefore, individuals with severe renal impairment should use Olaparib with caution. Severe renal impairment indicates a significant decrease in kidney function, often reflected in low levels of creatinine clearance. Such patients may require dose adjustments or close monitoring while taking Olaparib to prevent complications.
It is worth noting that the information provided in this article is not exhaustive, and it is vital for individuals considering Olaparib treatment to consult their healthcare providers for a complete evaluation of their medical history, underlying conditions, and potential contraindications.
In summary, Olaparib is a valuable medication in the management of various cancers. However, it is contraindicated in individuals with known hypersensitivity to the drug. Moreover, its use during pregnancy and breastfeeding is not recommended due to limited data on its safety. Individuals with severe hepatic or renal impairment should exercise caution when using Olaparib and ensure regular monitoring by healthcare professionals. As with any medication, it is crucial to discuss the risks and benefits of Olaparib with your healthcare provider to make informed treatment decisions.
功能主治:新型的PARP抑制剂,用于治疗晚期卵巢癌,乳腺癌等
用法用量:用法用量 1、本品应在有抗肿瘤药物使用经验的医生的指导下使用。 2、推荐剂量:本品有150mg和100mg规格。 推荐剂量为300mg(2片150mg片剂),每日2次,相当于每日总剂量为600mg。 100mg片剂在剂量减少时使用。 3、患者应在含铂化疗结束后的8周内开始本品治疗,持续治疗直至疾病进展或发生不可接受的毒性反应。 4、给药方法:口服给药。 本品应整片吞服,不应咀嚼、压碎、溶解或掰断药片。 本品在进餐或空腹时均可服用。 5、漏服:如果患者漏服一剂药物,应按计划时间正常服用下一剂量。 6、避免同时使用强或中度CYP3A抑制剂,如果不能避免同时使用,减少奥拉帕利的剂量到: 6.1与强效CYP3A抑制剂同时使用,变更为100mg,每日两次。 6.2与中度CYP3A抑制剂同时使用,变更为150mg,每天两次。 7、对于有中度肾损害的患者,将奥拉帕尼的剂量减少到200mg,每天2次